TriSalus Life Sciences Inc. (TLSI)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $140.06M
Last updated: Nov 17, 2026 at 4:26 PM ET
TriSalus Life Sciences Inc. (TLSI) Statistics
TriSalus Life Sciences (TLSI) has a market cap of $140.06M and an enterprise value of $131.37M. Its share count is up 35.80% from a year earlier. It kept -56.60% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 6.20% below the market cap, as cash exceeds debt.
| Market Cap | $140.06M |
|---|---|
| Enterprise Value | $131.37M |
| Latest price (Nov 17, 2026) | $2.29 |
Key Dates
| Last Earnings Date | Nov 10, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.9x and 198.8x. Its year-end P/S ranged from 0.8x to 5.8x from 2023 to 2025.
| P/S Ratio | 2.9x |
|---|---|
| Forward P/S | 3.0x |
| P/B Ratio | 198.8x |
Price Statistics
The stock is down 49.67% over 52 weeks and trades 41.88% below its 50-day average.
| Beta (1Y) | 1.26 |
|---|---|
| 52-Week Change | -49.67% |
| 1-Month Change | -34.99% |
| 3-Month Change | -58.20% |
| 6-Month Change | -27.14% |
| Total Return (1Y) | -49.67% |
| Total Return (3Y CAGR) | -15.62% |
| Return vs SPY (1Y) | -61.67% |
| Max Drawdown (1Y) | -69.73% |
| Max Drawdown (3Y) | -77.85% |
| Sharpe Ratio (1Y) | -0.77 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $3.94 |
| 200-Day Average | $4.26 |
| 52-Week Range | $2.17 to $7.95 |
| RSI (14 Days) | 26.9 |
| Average Volume (20 Days) | 315.33K |
Financial Position
Current assets cover 4.22x current liabilities, and total debt is 47.60x shareholder equity.
| Current Ratio | 4.22x |
|---|---|
| Quick Ratio | 3.86x |
| Debt / Equity | 47.60x |
| Interest Coverage | -3.62x |
Returns and Efficiency
Return on invested capital is -65.01% and return on equity is -3861.03% over the last 12 months.
| Return on Equity (ROE) | -3861.03% |
|---|---|
| Return on Assets (ROA) | -45.61% |
| Return on Invested Capital (ROIC) | -65.01% |
| Return on Capital Employed (ROCE) | -48.23% |
| Asset Turnover | 0.99x |
| Inventory Turnover | 1.42x |
| Receivables Turnover | 7.37x |
| Cash Conversion Cycle | 74 days |
Scores
TLSI has an Altman Z-Score of -6.58, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -6.58 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $46.39M over the last 12 months is up 15.38% from the 12 months before.
| Revenue | $46.39M |
|---|---|
| Revenue Growth (YoY) | +15.38% |
| Gross Profit | $40.11M |
| Operating Income | -$29.20M |
| Pretax Income | -$26.24M |
| Net Income | -$26.25M |
| EBITDA | -$19.65M |
| EBIT | -$21.48M |
| Reported EPS (TTM) | -$0.33 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 1.18% of the $57.56M in total assets.
| Cash and Equivalents | $41.06M |
|---|---|
| Total Debt | $32.37M |
| Net Cash | $8.69M |
| Net Cash Per Share | $0.15 |
| Working Capital | $41.88M |
| Shareholder Equity | $680.00K |
| Book Value Per Share | $0.01 |
| Total Assets | $57.56M |
| Total Liabilities | $56.88M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $354.00K of capital spending, operating cash flow left -$24.72M of free cash flow.
| Operating Cash Flow | -$24.37M |
|---|---|
| Capital Expenditures | $354.00K |
| Free Cash Flow | -$24.72M |
| FCF Per Share | -$0.40 |
| Depreciation and Amortization | $1.83M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -62.95%.
| Gross Margin | 86.46% |
|---|---|
| Operating Margin | -62.95% |
| Pretax Margin | -56.57% |
| Net Margin | -56.60% |
| EBITDA Margin | -42.36% |
| EBIT Margin | -46.31% |
| FCF Margin | -53.29% |
Dividends and Yields
TLSI does not pay a dividend. Its free cash flow yield is -18.42%.
| FCF Yield | -18.42% |
|---|---|
| Buyback Yield | -32.11% |
| Shareholder Yield | -32.11% |
Peer Position
Against 11 similar companies, TLSI has the 4th highest P/S.
P/S RatioPeer median 1.4x
ROICPeer median -23.33%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +1.60%
| P/S Ratio | 2.9x vs 1.4x median |
|---|---|
| ROIC | -65.01% vs -23.33% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +15.38% vs +1.60% median |
Analyst Forecast
Consensus estimates put revenue growth at 14.76% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +14.76% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TLSI
What is TLSI's market cap?
TriSalus Life Sciences has a market cap of $140.06M. Its enterprise value, which adds debt and subtracts cash, is $131.37M.
How many shares of TLSI are outstanding?
TriSalus Life Sciences has 58.47M shares outstanding. The count is up 35.80% from a year earlier.
Does TLSI pay a dividend?
No. TriSalus Life Sciences does not pay a dividend.
How much debt does TLSI have?
TriSalus Life Sciences has $32.37M of total debt and $41.06M of cash and equivalents, a net cash position of $8.69M.
TLSI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors